MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
48.19
+0.14 (0.29%)
Oct 29, 2024, 4:00 PM EDT - Market closed
MLTX Employees
MoonLake Immunotherapeutics had 50 employees as of December 31, 2023. The number of employees increased by 30 or 150.00% compared to the previous year.
Employees
50
Change (1Y)
30
Growth (1Y)
150.00%
Revenue / Employee
n/a
Profits / Employee
-$1,096,076
Market Cap
3.03B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 50 | 30 | 150.00% |
Dec 31, 2022 | 20 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Bausch Health Companies | 20,270 |
Amedisys | 19,000 |
Neogen | 2,917 |
LivaNova | 2,900 |
PTC Therapeutics | 1,055 |
Rhythm Pharmaceuticals | 226 |
Scholar Rock Holding | 150 |
Dyne Therapeutics | 141 |
MLTX News
- 7 weeks ago - MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 - GlobeNewsWire
- 3 months ago - MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward - Seeking Alpha
- 5 months ago - MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa - GlobeNewsWire
- 6 months ago - MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion - Seeking Alpha
- 6 months ago - MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 7 months ago - MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions - GlobeNewsWire
- 7 months ago - MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions - Business Wire
- 8 months ago - MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day - GlobeNewsWire